| Literature DB >> 32518485 |
Nu Altintas1, S A Karamil1, O Turkum1, M Akil2, A Sakarya3, H Bozkaya4, J Šoltys5, Na Altintas2.
Abstract
The aim of this study was to investigate whether Enzyme-Linked Immunosorbent Assays (ELISA) and Western Blotting (WB) methods could contribute to the assessment of clinical outcomes in genotype-defined cystic echinococcosis (CE) patients. Twenty-nine human isolates and blood samples have been taken from patients who underwent surgery or percutaneous aspiration (PAIR) for therapeutic purposes at Ege University and Manisa Celal Bayar University Hospitals. All sera of patients were screened for the presence of E. granulosus IgG antibodies using in-house approved ELISA and WB methods. According to the ELISA results, five patients had high, thirteen patients had medium and eight patients had low specific antibody level response which ranged 1/640 -1/5000. Despite confirmed WB positivity three patients were found to be negative by ELISA. Immunoblot analysis of EgAg showed many protein bands with size of 8, 12, 20, 22, 24, 36, 75 and 90 kDa. Among of them, 8 - 12 kDa bands (90 %), 20 - 22 kDa and 36 kDa bands presented strong reactivity against human serum specimens. No serum samples from healthy control reacted with EgAg. Phylogenetic analysis of resulting COX1 and NAD1sequences has revealed that all patients in our study were infected with the E. granulosus G1-G3 genotype. There was no consistent correlation between results of ELISA and WB, the number or size of cysts and genotype. Our study brings a unique contribution in terms of relationship between serological investigation, disease genotypes and clinical outcomes.Entities:
Keywords: Cystic echinococcosis; ELISA; sequence analysis; serology; western blotting
Year: 2020 PMID: 32518485 PMCID: PMC7261030 DOI: 10.2478/helm-2020-0012
Source DB: PubMed Journal: Helminthologia ISSN: 0440-6605 Impact factor: 1.184
Oligonucleotide primers used in PCR and DNA Sequencing for typing of Echinococcus granulosus.
| Primers | Gene Regions | Nucleotide Sequences | Sources |
|---|---|---|---|
| MS1 | NAD1 | CGTAGGTATGTTGGTTTGTTTGGT | Sharbatkhori et al., 2009 |
| MS2 | NAD1 | CATAATCAAATGGCGTACGAT | Sharbatkhori et al., 2009 |
| JB3 | CO1 | TTTTTTGGGCATCCTGAGGTTTAT | |
| JB4.5 | CO1 | TAAAGAAAGAACATAATGAAAATG | |
| BD1 | ITS-1 | GTCGTAACAAGGTTTCCGTA | Bowless & McManus, 1993 |
| 4S | ITS-1 | TCTAGATGCGTTCGAA(G/A)TGTCGATG | Bowless & McManus, 1993 |
Gender and age, ELISA and Western Blot results, organ localization, molecular identification and clinical symptoms, drug used and dog owner informations of the 29 CE cases.
| No of patient | Gender | Age | Province | ELISA Od value / Evaluation | WB bands ( kDa) | Organ localisation | Genotype of | Drug Used /NA | Dog owner | Clinical symptoms |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 29 | Kütahya | 2,403/H | 12,20-22,36,75,90 | Liver right lobe | Y | Y | Mild pain | |
| 2 | M | 36 | İzmir | 2,859/H | 812,20-22,36,75,90 | Liver right lobe seg. 6-7 | E. | Y | N | Pain, palpable mass, headache |
| 3 | M | 12 | Izmir | 1,047/M | 8,12,20-22,36,75,90 | Liver right lobe posterior | E. | Y | N | Pain |
| 4 | F | 31 | Bornova/İzmir | 0,792/M | 12,20-22,36,75,90 | Liver right lobe seg. 6-7 | E. | Y | N | Pain, vomiting |
| 5 | M | 36 | Bergama/İzmir | 0,865/M | 8,12,20-22,36,75,90 | Liver left lobe seg. 7 | E. | Y | Y | Palpable mass, pain, nausea, vomiting, |
| 6 | M | 63 | Karabağlar/İzmir | 2,069/H | 8,12,20-22,36,75,90 | Liver right 4A-B | E. | Y | N | Pain |
| 7 | M | 53 | Izmir | 0,498/L | 12, 36 (low), 75, 90 | Liver seg. 4-5-6 | E. | Y | N | Palpable mass, pain, weakness, nausea |
| 8 | M | 23 | Manisa | 0,974/M | 20-22, 36, 75, 90 | Liver right lobe | E. | Y | Y | Palpable mass, pain |
| 9 | M | 42 | İzmir | 0,469/L | 12, 20-22, 36 (low), 75, 90 | Liver right 4A-B | E. | Y | N | Pain |
| 10 | M | 40 | Buca/İzmir | 1,032/M | 20-22, 36, 75, 90 | Liver hilum | E. | N | Y | Pain |
| 11 | F | 30 | İzmir | 0,831/M | 12, 36 (low), 90 | Liver right 4B | E. | Y | Y | Pain, nausea, vomiting |
| 12 | F | 13 | Merkez/Aydın | 1,569/H | 12,20-22,36,75,90 | Liver | E. | Y | N | Pain, nausea, vomiting |
| 13 | F | 61 | Alaşehir/Manisa | 0,552/L | 20-22, 36, 75, 90 | Liver right lobe | E. | N | Y | Ağrı,çarpıntı |
| 14 | F | 49 | Denizli | 1,058/M | 8, 20-22, 36, 75, 90 | Liver | E. | N | Y | Pain, nausea |
| 15 | M | 49 | Söke/Aydın | 0,936/M | 8,12,20-22,36 | Liver | E. | Y | N | Pain, palpitations |
| 16 | M | 10 | Gömeç/Balıkesir | 0,099/N | 12, 20-22 (low) | Liver | E. | Y | Y | Palpable mass, pain, hepatomegaly, dizziness |
| 17 | F | 62 | Balıkesir | 0,454/L | 12,20-22,36,75,90 | Liver | E. | Y | Y | Severe pain, nausea, vomiting, jaundice |
| 18 | F | 19 | Aydın | 0,142/N | 20-22 (low) | Liver | E. | Y | Y | Palpable mass, severe pain |
| 19 | M | 59 | Akhisar/Manisa | 0,944/M | 36, 75, 90 | Liver | E. | Y | Y | Back stiffness, severe pain, hepatomegaly |
| 20 | M | 30 | Balıkesir | 1,018/M | 20-22, 36, 75, 90 | Liver | E. | Y | N | Severe pain, nausea, vomiting, jaundice |
| 21 | F | 15 | Bornova/İzmir | 0,243/N | 12,36,75 | Liver | E. | Y | N | Severe pain, nausea |
| 22 | M | 15 | Izmir | 0,551/L | 8, 20-22, 36, 75, 90 | Liver | E. | Y | N | Palpable mass, pain |
| 23 | F | 52 | Menemen/İzmir | 1,063/M | 8, 20-22, 36, 75, 90 | Liver | E. | Y | Y | Pain |
| 24 | M | 8 | Ayvalık/Balıkesir | 0,649/L | 8,12,20-22,36,75,90 | Liver | E. | Y | Y | Palpable mass, fever, vomiting |
| 25 | M | 26 | Söke/Aydın | 0,649/L | 8,12,20-22,36,75,90 | Liver | E. | Y | Y | Severe pain, swelling |
| 26 | M | 19 | Akhisar/Manisa | 1,066/M | 8,12,20-22,36,75,90 | Liver | E. | Y | N | Pain |
| 27 | F | 10 | Manisa | 0,498/L | 12,20-22 | Liver | E. | Y | N | Pain, loss of appetite, anemia |
| 28 | M | 48 | Muğla | 1,262/H | 8,12,20-22,36,75,90 | Liver | E. | Y | Y | Vomiting, weakness, hepatomegaly |
| 29 | M | 10 | Izmir | 1,047/M | 8,12,20-22,36,75,90 | Liver | E. | Y | Y | Palpable mass, nausea, vomiting |
ELISA: H: High, M: Medium, L: Low, N: Negative. Cut off value: 0,382
Drug used and dog owner: Y: Yes, N: No.
Drug used: NA (duration is not available)
Fig. 1Western Blot analysis of patient sera using HF (HF-WB). The lines represent: 1-Positive Control, 2-Negative Control, 3-22 Sera with confirmed CE.
Fig. 2CO1, NAD1 and ITS-1 Gene Amplicons. A. CO1 gene amplicons (446 bp). M:DNA Marker, 1:Positive Control, 2-3:Human Isolates, 4:Negative Control (Distilled water) B. NAD1 gene amplicons (378 bp). M:DNA Marker, 1:Positive Control, 2:Negative Control (Distilled water), 3-4:Human Isolates. C. ITS-1 gene amplicons. M:DNA Marker, 1:Positive Control, 2:Negative Control (Distilled water), 3:Human.
Age and gender distribution of CE patients.
| Patient Age | Male | Female | Total |
|---|---|---|---|
| 0 – 12 | 4 | 1 | 5 |
| 13 – 20 | 2 | 3 | 5 |
| 21 – 35 | 3 | 2 | 5 |
| 36 + | 10 | 4 | 14 |
| Total | 19 | 10 | 29 |
Fig. 3A map of Turkey showing the distribution of 29 CE cases province caused by E. granulosus.